Insulin remains the only treatment for patients with Type 1 Diabetes. Research continues today to try to find a faster acting and more consistent form of insulin. Historically, insulin studies have been conducted at the BDC that led to the approval of the rapid acting insulins Humalog (Diabet Med, 1996) , Novolog and Apidra (1990s to mid-2000’s) (DTT, 2005) and of the long acting insulin Lantus U-100 (2000). In the past decade research has been conducted on new long acting insulins Toujeo (Lantus U-300) and Tresiba. Insulin with different additives that can affect the absorption rate have also been studied at the BDC, these include Halozyme (Diabetes Obes Metab, 2014) and Diasome. Studies are currently being conducted on new Ultra Rapid acting Lispro for use in MDI and insulin pumps (J Diabetes Sci Technol, 2011).
In addition to injectable insulin the BDC has studied other routes to take insulin such as buccal and inhaled insulin (Drug Discov Today, 2019). Lilly, Novo Nordisk and Pfizer have all studied inhaled insulin, but the only inhaled insulin that is still on the market is Afrezza by MannKind which was recently evaluated at the BDC (DTT, 2018), (DTT, 2018).
